Paul A. Bevins

Paul A. Bevins

Auto-generated profile, based on publicly available information

Paul A. Bevins

Department of Medicine, University of Louisville School of Medicine, KY 40202, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
LJLuke Johnson
Luke Johnson
DHDat T. Ha
Dat T. Ha
MHMelissa B. Hall
Melissa B. Hall
GSGregory Shoemaker
Gregory Shoemaker
PBPaul A. Bevins
Paul A. Bevins
JJJoongho John Joh
Joongho John Joh
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( ) with 100% specificity as a predictive test.